neurology

News

Laquinimod failure is bad news for Teva's MS hopes

Teva has been forced to abandon laquinimod in relapsing-remitting multiple sclerosis, after it missed a target related to disability progression in a late stage trial.

News

Will Gottlieb follow up on Trump's promise of a bonfire of regulations?

FDA approves first ALS treatment for two decades

FDA asked Mitsubishi to file Radicava following approval in Japan.

News

Biotech IPO market heats up as BioHaven's debut impresses

BioHaven raises $168 million with biggest biotech IPO seen this year.

News

Biogen shares up after strong launch for rare disease drug

US insurers are covering the treatment, despite high price.

News

FDA approves Teva's Huntington's Disease drug

First treatment approved for Huntington's Disease in almost a decade.

News

Sucampo buys rare disease firm Vtesse

Sucampo gains rights to a drug for rare genetic disorder.

Laquinimod failure is bad news for Teva's MS hopes

FDA approves first ALS treatment for two decades

Biotech IPO market heats up as BioHaven's debut impresses

Biogen shares up after strong launch for rare disease drug

FDA approves Teva's Huntington's Disease drug

Sucampo buys rare disease firm Vtesse

GBL joins CVC in €10.7bn takeover bid for Recordati

Discover a new era of healthcare panel engagement: Grounded ...

neurology

Editor's Picks